Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer.

Keeley BR, Islami F, Pourshams A, Poustchi H, Pak JS, Brennan P, Khademi H, Genden EM, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R, Sikora AG.

Cancer Sci. 2014 Sep;105(9):1205-11. doi: 10.1111/cas.12485. Epub 2014 Sep 3.

2.

Circulating inflammation markers and prospective risk for lung cancer.

Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, Katki HA, Koshiol J, Shelton G, Caporaso NE, Pinto LA, Chaturvedi AK.

J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80. doi: 10.1093/jnci/djt309. Epub 2013 Nov 18.

3.

Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies.

Brenner DR, Fanidi A, Grankvist K, Muller DC, Brennan P, Manjer J, Byrnes G, Hodge A, Severi G, Giles GG, Johansson M, Johansson M.

Am J Epidemiol. 2017 Jan 15;185(2):86-95. doi: 10.1093/aje/kww159. Epub 2016 Dec 20.

PMID:
27998891
4.
5.

Serum biomarkers in head and neck squamous cell cancer.

Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CA.

JAMA Otolaryngol Head Neck Surg. 2014 Jan;140(1):5-11. doi: 10.1001/jamaoto.2013.5688.

PMID:
24232368
6.

Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers.

Łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.

Clin Chem Lab Med. 2010 Oct;48(10):1467-73. doi: 10.1515/CCLM.2010.274. Epub 2010 Jul 7.

PMID:
20604722
7.

Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer.

Mroczko B, Szmitkowski M, Niklinski J.

Clin Chem Lab Med. 2001 May;39(5):374-9.

PMID:
11434384
8.

Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.

Henry CJ, Sedjo RL, Rozhok A, Salstrom J, Ahnen D, Levin TR, D'Agostino R Jr, Haffner S, DeGregori J, Byers T.

BMC Cancer. 2015 Mar 14;15:123. doi: 10.1186/s12885-015-1115-2.

9.

Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.

Hübel K, Mansmann G, Schäfer H, Oberhäuser F, Diehl V, Engert A.

Cytokine. 2000 Dec;12(12):1797-800.

PMID:
11097751
10.

Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature.

DeCotiis C, Hu Y, Greenberg AK, Huie M, Tsay JC, Pass H, Goldberg JD, Rom WN.

Cancer Biomark. 2016;16(2):219-33. doi: 10.3233/CBM-150559. Review.

PMID:
26756613
11.

Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.

Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J.

Oncology. 2006;70(2):115-25. Epub 2006 Apr 26.

PMID:
16645324
12.

Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C.

Clin Cancer Res. 1999 Jun;5(6):1369-79.

13.

Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers.

Xu J, Chen Y, Zhang R, Song Y, Cao J, Bi N, Wang J, He J, Bai J, Dong L, Wang L, Zhan Q, Abliz Z.

Mol Cell Proteomics. 2013 May;12(5):1306-18. doi: 10.1074/mcp.M112.022830. Epub 2013 Feb 8.

14.

An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis.

Yang YF, Li H, Xu XQ, Diao YT, Fang XQ, Wang Y, Zhao DL, Wu K, Li HQ.

Dis Esophagus. 2008;21(5):395-401. doi: 10.1111/j.1442-2050.2007.00789.x.

PMID:
19125792
15.

Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.

Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, Hong E, Chmielewski G, Yoder MA, Shah PN, Edell ES, Maldonado F, Bungum AO, Borgia JA.

J Thorac Oncol. 2013 Jan;8(1):31-6. doi: 10.1097/JTO.0b013e31827627f8.

16.

Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study.

Liu KD, Altmann C, Smits G, Krawczeski CD, Edelstein CL, Devarajan P, Faubel S.

Crit Care. 2009;13(4):R104. doi: 10.1186/cc7940. Epub 2009 Jul 1.

17.

Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.

Łukaszewicz-Zając M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.

Dis Esophagus. 2012 Apr;25(3):242-9. doi: 10.1111/j.1442-2050.2011.01242.x. Epub 2011 Sep 2.

PMID:
21895853
18.

Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients.

Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Myśliwiec P, Kedra B, Szmitkowski M.

Clin Chem Lab Med. 2007;45(1):30-4.

PMID:
17243911
19.

Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.

Park J, Yang JS, Jung G, Woo HI, Park HD, Kim JW, Huh W, Ko JW, Kim H, Cho JY, Lee SY.

J Proteomics. 2013 Dec 6;94:302-10. doi: 10.1016/j.jprot.2013.09.019. Epub 2013 Oct 11.

PMID:
24120528
20.

Serum miR-1297: a promising diagnostic biomarker in esophageal squamous cell carcinoma.

Wang C, Li Q, Liu F, Chen X, Nesa EU, Guan S, Liu B, Han L, Tan B, Wang D, Chen P, Liu X, Zhang H, Sun Y, Cheng Y.

Biomarkers. 2016 Sep;21(6):517-22. doi: 10.3109/1354750X.2016.1160291. Epub 2016 May 6.

PMID:
27152453

Supplemental Content

Support Center